US OK for Akorn’s first lyophilised product

By Gareth Macdonald

- Last updated on GMT

Related tags: Food and drug administration, Pharmacology, Akorn

The FDA has granted sNDA approval for Akorn’s IC-Green injection dye, which is the first lyophilised product manufacturered at the firm’s Decatur facility to gain such status.

In recent years, Akorn has invested around $23m (€16.3m) in new liquid and lyophilised injectables manufacturing fill line capacity at its Illinois production facility.

In December last year, the US Food and Drug Administration (FDA) completed a pre-approval inspection (PAI) of the plant, clearing Akorn to begin both in-house and contract lyophilisation operations.

Arthur Przybyl, Akorn's CEO, said: "We intend to commercialise our lyophilisation manufacturing capabilities by developing an internal abbreviated new drug application (ANDA) injectable product line and by expanding our contract pharmaceutical manufacturing business segment to include lyophilised injectable products."

The market for contract lyophilisation, a vacuum method for freeze drying compounds that maintains their physical structure, is continuing to expand as drugmakers increasingly turn to industry experts to apply this expensive specialist technique.

While contracting giant Patheon dominates the global scene with its facilities in Ferentino and Monza, Italy and lyophilised cephalosporin plant in Swindon in the UK, the growing demand for improved drug stability means that there are still plenty of opportunities in the market.

Dexamethasone Sodium Phosphate ANDA

In related news, Akorn said it has received FDA clearance for its dexamethasone sodium phosphate injection. The drug, which has an estimated annual market size of $28m according to IMS Health, treats a wide range of conditions including endocrine disorders, arthritis, and blood and dermatologic diseases.

Dexamethasone sodium phosphate​was developed by the Akorn-Strides joint venture, which is focused on the development of liquid, lyophilized and dry powder formulations of generic injectable products targeting several therapeutic markets with a major focus on anti-infectives, analgesics and central nervous system (CNS) medicines.

At present, the enterprise has a portfolio of 29 ANDAs and a total of 53 product line offerings. To date, the firm has filed 18 ANDAs with the FDA, 11 of which have been approved.

In its most recent financial statement, Akorn revealed that the joint venture generated revenue in the third quarter of 2008, the majority of which was from sales of its product Rifampin.

Related topics: Ingredients, Processing equipment

Related news

Show more

Related products

The battle of performance in pharma production

The battle of performance in pharma production

Telstar Life Science Solutions | 26-Mar-2019 | Case Study

Telstar case study. Discover how a versatile freeze-dryer automatic loading & unloading systemDiscover how a versatile freeze-dryer automatic loading...

Accelerate your supply chain as pressures intensify

Accelerate your supply chain as pressures intensify

William Reed | 17-Sep-2018 | Technical / White Paper

Food, Drink and Non-Food manufacturers are under pressure. Range reviews, massive retail mergers, the backlash against plastic packaging and the ongoing...


Optimizing vessel geometry for mag drive agitators

Steridose, Inc | 14-Sep-2017 | Technical / White Paper

The performance of a bottom mount magnetically driven agitator (mag drive mixer) is heavily dependent on its relationship with the vessel’s geometry, baffles,...

Related suppliers